Annual report
9987.TEDINET S100R3L5
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.13T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.21T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.13T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥32.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥20.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥41.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥36.2bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥30.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.5bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥28.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥30.2bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥14.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.11T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.19T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥417.9bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥412.7bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥401.6bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥132.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥175.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥217.0bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥37.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥15.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥25.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥46.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥26.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥17.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥27.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.52 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥310.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥322.73 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,970.38 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,749.59 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,675.23 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,618.33 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,390.98 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.4% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,429 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 14,032 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 15,041 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 15,477 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 15,585 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥2.12T | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥2.04T | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥1.93T | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.00T | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.92T | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥10.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥24.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥11.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥30.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.5bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥18.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥14.9bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥13.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥6.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥21.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥24.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.05T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.03T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.00T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.00T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.08T | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥758.9bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥723.8bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥290.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥302.5bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥303.2bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥301.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥296.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥85.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥172.97 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.55 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.15 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥238.38 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥263.43 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥69 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,515 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,440.25 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,398.64 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,375.27 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,244.37 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 27.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 82,831,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,232 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,430 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,116 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,244 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 4,401 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 75
| Segment | Item | Period | Value |
|---|---|---|---|
| The Healthcare Related Services Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| The Healthcare Related Services Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥658m |
| The Healthcare Related Services Businessreportable segment | employees | at 2023-03-31 | 1586 pure |
| The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥228.7bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥39.4bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥189.3bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2023-03-31 | ¥78.4bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| The Insurance Pharmacy Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥589m |
| The Insurance Pharmacy Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥667m |
| The Insurance Pharmacy Businessreportable segment | employees | at 2023-03-31 | 2876 pure |
| The Insurance Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥87.7bn |
| The Insurance Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥87.7bn |
| The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥23m |
| The Insurance Pharmacy Businessreportable segment | segment assets | at 2023-03-31 | ¥37.6bn |
| The Insurance Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.6bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2023-03-31 | 8143 pure |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.23T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.18T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥49.9bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2023-03-31 | ¥972.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥27.1bn |
| The Pharmaceutical Manufacturing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥429m |
| The Pharmaceutical Manufacturing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥615m |
| The Pharmaceutical Manufacturing Businessreportable segment | employees | at 2023-03-31 | 824 pure |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥44.4bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.6bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥33.7bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment assets | at 2023-03-31 | ¥60.5bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥17.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.31T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥272.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.15T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥32.3bn |
| The Healthcare Related Services Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥570m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥633m |
| The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥181.8bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥39.0bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥142.8bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2022-03-31 | ¥63.7bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| The Insurance Pharmacy Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥703m |
| The Insurance Pharmacy Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥747m |
| The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥88.8bn |
| The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥88.8bn |
| The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥34m |
| The Insurance Pharmacy Businessreportable segment | segment assets | at 2022-03-31 | ¥38.9bn |
| The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.3bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥13.1bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥7.3bn |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.15T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.10T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥51.6bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2022-03-31 | ¥980.9bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥14.7bn |
| The Pharmaceutical Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥549m |
| The Pharmaceutical Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥913m |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥43.9bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥12.2bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥31.7bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥59.0bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥780m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.47T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.24T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥226.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥20.0bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2023-03-31 | 3232 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,996
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)旭化成㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row18Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)持田製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)ゼリア新薬工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Original text (Japanese)科研製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row22Member | Original text (Japanese)ウエルシアホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row22Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row22Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row23Member | Original text (Japanese)㈱マツキヨココカラ＆カンパニー | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row23Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row23Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row24Member | ㈱Welby | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row24Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row24Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row25Member | Original text (Japanese)㈱ツルハホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row25Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row25Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row26Member | Original text (Japanese)住友化学㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row26Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row26Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row27Member | Original text (Japanese)中外製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row27Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row27Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row28Member | Original text (Japanese)㈱セブン＆アイ・ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row28Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row28Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row29Member | Original text (Japanese)わかもと製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row29Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row29Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row30Member | Original text (Japanese)住友ファーマ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row30Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row30Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row31Member | Original text (Japanese)㈱サンドラッグ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row31Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row31Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)扶桑薬品工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)堺化学工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)㈱アインホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |